What Is The Leading Driver Behind Rise In Prevalence Of Kidney Cancer Drives Growth In The Diagnostics And Therapeutics Market Market Expansion in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Kidney Cancer Diagnostics And Therapeutics Industry Market Size Be by 2025?
The sphere encompassing kidney cancer diagnosis and treatment modalities has experienced a robust surge recently, projecting an expansion from a valuation of $4.1 billion in the year 2024 to $4.31 billion by 2025, which equates to a consistent annual growth rate (CAGR) of 5.1 %. This upward trajectory observed throughout the past period stems from advancements in molecular biology research, ongoing clinical trials and the subsequent development of new pharmaceuticals, significant strides in surgical techniques, important genetic insights being uncovered, and enhancements in the accessibility of medical services.

What's the Long-Term Growth Forecast for the Kidney Cancer Diagnostics And Therapeutics Market Size Through 2029?
Anticipated robust expansion characterizes the trajectory for the kidney cancer diagnostics and therapeutics sector, projecting its valuation to reach $5.65 billion by the year 2029, underpinned by a compound annual growth rate (CAGR) of seven percent. This forward momentum throughout the forecast duration stems from several key drivers: ongoing biomarker investigations, progress in genomic sequencing methodologies, the increasing use of telemedicine and virtual consultations, strides in precision medicine, and the development of swift diagnostic tools. Furthermore, several significant shifts are shaping the market landscape during this period, notably the incorporation of palliative care strategies, a greater focus on extended survivorship support, the incorporation of nutritional and lifestyle recommendations, the widening application of radiomics, and the growing acceptance of liquid biopsy techniques.

View the full report here:
https://www.thebusinessresearchcompany.com/report/kidney-cancer-diagnostics-and-therapeutics-global-market-report

What Are the Key Growth Drivers Fueling the Kidney Cancer Diagnostics And Therapeutics Market Expansion?
The escalating incidence of kidney cancer is anticipated to fuel the expansion of the market for diagnostics and treatments related to this condition. Kidney cancer is characterized by the aberrant development and unrestricted proliferation of typical kidney cells, leading to the creation of a mass identified as a renal cortical tumor within one or both kidneys. Procedures and medications used for diagnosing and treating kidney cancer are vital in handling and curing the ailment, presenting numerous advantages for those affected, including the ability to spot the disease early, confirm diagnoses precisely, assist in choosing therapeutic approaches, enable customized care, and track treatment efficacy. For example, data from the American Society of Clinical Oncology (ASCO), a US-based entity dedicated to cancer management, indicated that projections for 2023 estimated 81,800 new cases of kidney cancer in the United States (divided between 52,360 men and 29,440 women), whereas in 2020, the global count of individuals living with kidney cancer reached 431,288. Consequently, the expanding occurrence of kidney cancer is set to be a major impetus for the advancement of the kidney cancer diagnostics and therapeutics marketplace.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11937&type=smp

What Are the Key Trends Driving Kidney Cancer Diagnostics And Therapeutics Market Growth?
The leading enterprises within the sphere of kidney cancer diagnostics and treatments are concentrating efforts on engineering sophisticated solutions for renal cell carcinoma (RCC) to enhance results for those affected and introduce novel therapeutic avenues customized for individuals confronting this difficult illness. Exploration of renal cell carcinoma (RCC) is fundamental to the progress of kidney cancer diagnostics and therapeutics, facilitating the genesis of cutting-edge detection techniques and precise treatments leading to earlier identification and personalized care for patients. As an illustration, in December of 2023, the American pharmaceutical giant Merck introduced welireg (belzutifan), which marked the initial approval of a hypoxia-inducible factor-2 alpha (HIF-2a) inhibitor designated for adult patients suffering from advanced renal cell carcinoma (RCC) subsequent to receiving prior therapy involving PD-1 or PD-L1 inhibitors alongside VEGF-TKIs. This innovative category of medication demonstrates notable advantages, such as prolonged progression-free survival durations and superior response percentages when benchmarked against everolimus. The authorization granted to WELIREG signifies a pivotal step forward in the kidney cancer diagnostics and therapeutics sector, bringing renewed optimism to patients experiencing disease progression.

How Is the Kidney Cancer Diagnostics And Therapeutics Market Segmented?
The kidney cancer diagnostics and therapeuticsmarket covered in this report is segmented -

1) By Cancer Type: Clear Cell RCC; Papillary RCC; Chromophobe RCC; Urothelial Carcinoma And Transitional Cell Carcinoma; Other Cancer Types
2) By Component: Drugs; Diagnostics
3) By Diagnostics: Biopsy; CT Scan; Nephro-Ureteroscopy; Intravenous Pyelogram; Ultrasound
4) By Therapy: Targeted Therapy; Immunotherapy; Chemotherapy
5) By End-Users: Hospitals; Pharmaceutical Labs; Genomics Laboratories

Subsegments:
1) By Clear Cell RCC: Stage I; Stage II; Stage III; Stage IV
2) By Papillary RCC: Type 1; Type 2
3) By Chromophobe RCC: Localized; Advanced
4) By Urothelial Carcinoma And Transitional Cell Carcinoma: Non-muscle invasive; Muscle invasive; Metastatic
5) By Other Cancer Types: Collecting Duct Carcinoma; Renal Medullary Carcinoma; Other rare types

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=11937&type=smp

Which Companies Are Leading the Charge in Kidney Cancer Diagnostics And Therapeutics Market Innovation?
Major companies operating in the kidney cancer diagnostics and therapeutics market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A, Bristol-Myers Squibb Pharmaceuticals Limited, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Amgen Inc., Siemens Healthcare GmbH, Laboratory Corporation of America Holdings, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd., Illumina Inc., PerkinElmer Inc., Ipsen S.A, Bio-Rad Laboratories Inc., QIAGEN NV, Exelixis Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., GeneDx LLC, CD Genomics, Genpath Life Sciences Private Limited

Which Regions Are Leading the Global Kidney Cancer Diagnostics And Therapeutics Market in Revenue?
North America was the largest region in the kidney cancer diagnostics and therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney cancer diagnostics and therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11937

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.